CDP323 Biomarker Study

Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

Inclusion Criteria:

• Female and male subjects aged 18-65 years
• Relapsing form of MS with at least one clinical relapse in the 24 months before screening;
• Screening EDSS score of 0-6.5;
• Must be fully immunocompetent
• Female subjects of childbearing potential must agree to practice contraception methods

Exclusion Criteria:

• Any conditions that could interfere with the contrast-enhanced MRI;
• Any clinically significant disease state or findings other than MS;
• Any clinically significant deviation from the pre-defined ranges for laboratory tests;
• Concomitant treatment with MS disease modifying drugs